Empyema, Pleural

脓胸,胸膜
  • 文章类型: Journal Article
    胸膜脓胸是小儿肺炎的严重并发症。细菌培养阴性通常会阻碍最佳抗生素治疗。为了提高细菌鉴定,我们开发了一种分子检测方法,并与细菌培养进行了比较。我们的多重定量PCR检测肺炎链球菌,化脓性链球菌,使用细菌基因组DNA和实验室制备的样品(n=267)评估了金黄色葡萄球菌和流感嗜血杆菌。为了评估临床表现,我们进行了胸部脓胸分子评估(MATE)观察性研究,登记患有脓胸住院的儿童。通过细菌培养和多重qPCR检测胸膜液,和使用研究黄金标准确定的性能。我们确定了临床敏感性和时间到生物体的鉴定,以评估多重qPCR减少经验性非靶向抗生素治疗持续时间的潜力。使用加标样品,多重qPCR对所有生物体均表现出213/215(99.1%)的敏感性和52/52(100%)的特异性.在2019年5月至2023年3月期间,有100名儿童参加了MATE研究;平均年龄为3.9岁(IQR2-5.6)。通过多重qPCR在90/100(90%)标本中鉴定出细菌病原体,细菌培养24/100(24%)(P<0.001)。多重qPCR在68/76(90%)培养阴性标本中鉴定出细菌原因。肺炎链球菌是最常见的病原体,在67/100(67%)标本中鉴定。我们估计我们的多重qPCR将减少61%病例中非靶向抗生素治疗的持续时间,中位数为20天(IQR17.5-23,范围1-55)。与培养物相比,多重qPCR显着增加了病原体检测,并且可以减少非靶向抗生素治疗的持续时间。
    Pleural empyema is a serious complication of pneumonia in children. Negative bacterial cultures commonly impede optimal antibiotic therapy. To improve bacterial identification, we developed a molecular assay and evaluated its performance compared with bacterial culture. Our multiplex-quantitative PCR to detect Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus and Haemophilus influenzae was assessed using bacterial genomic DNA and laboratory-prepared samples (n = 267). To evaluate clinical performance, we conducted the Molecular Assessment of Thoracic Empyema (MATE) observational study, enrolling children hospitalised with empyema. Pleural fluids were tested by bacterial culture and multiplex-qPCR, and performance determined using a study gold standard. We determined clinical sensitivity and time-to-organism-identification to assess the potential of the multiplex-qPCR to reduce the duration of empiric untargeted antibiotic therapy. Using spiked samples, the multiplex-qPCR demonstrated 213/215 (99.1%) sensitivity and 52/52 (100%) specificity for all organisms. During May 2019-March 2023, 100 children were enrolled in the MATE study; median age was 3.9 years (IQR 2-5.6). A bacterial pathogen was identified in 90/100 (90%) specimens by multiplex-qPCR, and 24/100 (24%) by bacterial culture (P <0.001). Multiplex-qPCR identified a bacterial cause in 68/76 (90%) culture-negative specimens. S. pneumoniae was the most common pathogen, identified in 67/100 (67%) specimens. We estimate our multiplex-qPCR would have reduced the duration of untargeted antibiotic therapy in 61% of cases by a median 20 days (IQR 17.5-23, range 1-55). Multiplex-qPCR significantly increased pathogen detection compared with culture and may allow for reducing the duration of untargeted antibiotic therapy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:本研究调查了经验性抗生素治疗(EAT),指导方针坚持,1402例小儿肺炎旁积液/胸膜脓胸(PPE/PE)住院患儿的抗生素精简和临床结局.
    方法:一项全国性的监测研究收集了有关EAT的数据,临床病程/结果,病原体,2010年至2018年德国PPE/PE儿童的药敏试验和抗生素精简。亚组比较采用χ2检验/Fisher精确检验,在适当情况下调整患者年龄的Mann-WhitneyU检验和线性回归分析。
    结果:提供了1402名儿童的完整EAT数据。在单药治疗的儿童(n=567)和2种抗生素联合治疗的儿童(n=589)中,最常用的抗生素是氨基青霉素/β-内酰胺酶抑制剂[138/567(24.3%)和102/589(17.3%)]和头孢呋辛[291/567(51.3%)和294/589(49.9%)].这些β-内酰胺类最常见的组合是大环内酯类,氨基糖苷类和克林霉素。我们观察到使用氨基青霉素/β-内酰胺酶抑制剂和头孢呋辛的EAT之间的临床严重程度/结果没有差异,无论是单药治疗还是2种抗生素联合治疗。肺炎链球菌的种类诊断(n=192),化脓性链球菌(n=111)或金黄色葡萄球菌(n=38)在聚合酶链反应或胸膜液或血液培养中导致9.4%的患者转向适当的窄谱β-内酰胺治疗,18.9%和5.2%的儿童。在有细菌药敏试验报告的儿童中,3/63(4.8%)的肺炎链球菌对青霉素耐药,10/32(31.3%)的儿童对金黄色葡萄球菌对甲氧西林耐药.
    结论:本研究指出PPE/PE患儿的抗生素过度治疗,特别是经常使用抗生素的组合。接受抗生素联合治疗的儿童在临床结局上没有差异。即使在病原体检测后,使用简化的抗生素治疗的儿童比率也很低,这表明在PPE/PE中需要抗生素管理措施,并且需要研究其他潜在的治疗策略作为抗炎治疗。
    OBJECTIVE: This study investigated empiric antibiotic treatment (EAT), guideline adherence, antibiotic streamlining and clinical outcomes in 1402 hospitalized children with pediatric parapneumonic effusion/pleural empyema (PPE/PE).
    METHODS: A nationwide surveillance study collected data on EAT, clinical course/outcome, pathogens, susceptibility testing and antibiotic streamlining of children with PPE/PE in Germany between 2010 and 2018. Subgroups were compared using χ2 test/Fisher exact test, Mann-Whitney U test and linear regression analysis adjusting for patient age where appropriate.
    RESULTS: Complete data on EAT were available for 1402 children. In children with monotherapy (n = 567) and in children with combination therapy of 2 antibiotics (n = 589), the most commonly used antibiotics were aminopenicillin/beta-lactamase inhibitor [138/567 (24.3%) and 102/589 (17.3%)] and cefuroxime [291/567 (51.3%) and 294/589 (49.9%)]. The most common combinations with these beta-lactams were macrolides, aminoglycosides and clindamycin. We observed no difference in clinical severity/outcome between EAT with aminopenicillin/beta-lactamase inhibitor and cefuroxime, neither when used in monotherapy nor when used in combination therapy of 2 antibiotics. Species diagnosis of Streptococcus pneumoniae (n = 192), Streptococcus pyogenes (n = 111) or Staphylococcus aureus (n = 38) in polymerase chain reaction or culture from pleural fluid or blood resulted in a switch to an appropriate narrow-spectrum beta-lactam therapy in 9.4%, 18.9 % and 5.2% of children. In a subset of children with reported bacterial susceptibility testing, penicillin resistance was reported in 3/63 (4.8%) of S. pneumoniae and methicillin resistance in S. aureus was reported in 10/32 (31.3%) of children.
    CONCLUSIONS: This study points to antibiotic overtreatment in children with PPE/PE, particularly the frequent use of combinations of antibiotics. Children receiving combinations of antibiotics did not show differences in clinical outcomes. The low rate of children with streamlined antibiotic therapy even upon pathogen detection indicates a necessity for antibiotic stewardship measures in PPE/PE and the need of investigating other potential therapeutic strategies as anti-inflammatory therapy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:局部麻醉下的胸腔镜检查广泛用于诊断恶性肿瘤和感染性疾病。然而,很少有报道描述该程序用于诊断和治疗胸腔内感染。本研究旨在评估局部麻醉下胸腔镜治疗胸腔内感染的安全性和有效性。
    结果:回顾性分析了2018年1月至2023年12月在我院接受胸科医师在局部麻醉下进行胸腔镜检查的患者的数据。我们分析了他们的人口因素,考试的原因,有针对性的疾病,检查长度,使用的麻醉方法,诊断和治疗成功率,以及任何不良事件。包括30名患者。其中,12人(40%)进行了胸腔镜检查以诊断感染,18人(60%)让他们治疗脓胸。在诊断胸膜炎方面,12例患者中只有3例(25.0%)通过胸腔镜检查发现了致病微生物.为了诊断脓胸,在18例患者中有7例(38.9%)被鉴定出致病微生物。耐甲氧西林金黄色葡萄球菌是最常见的致病微生物。治疗成功率很高,介于94.4和100%之间,而感染背后的致病微生物的识别率很低,介于25.0和38.9%之间。最常见的不良事件包括围手术期低氧血症和疼痛。有2例(6.7%)严重不良事件≥3级,但均未导致死亡。
    结论:在局部麻醉下通过胸腔镜治疗胸内感染的效果是值得称道的。尽管如此,该程序的诊断准确性,关于精确鉴定导致胸腔内感染的致病微生物,持续在相当低的水平,提出了一个巨大的临床障碍。
    OBJECTIVE: Thoracoscopy under local anaesthesia is widely performed to diagnose malignancies and infectious diseases. However, few reports have described the use of this procedure for diagnosing and treating intrathoracic infections. This study aimed to evaluate the safety and efficacy of thoracoscopy under local anaesthesia for the management of intrathoracic infections.
    RESULTS: Data from patients who underwent thoracoscopy procedures performed by chest physicians under local anaesthesia at our hospital between January 2018 and December 2023 were retrospectively reviewed. We analysed their demographic factors, reasons for the examinations, diseases targeted, examination lengths, anaesthetic methods used, diagnostic and treatment success rates, as well as any adverse events. Thirty patients were included. Of these, 12 (40%) had thoracoscopies to diagnose infections, and 18 (60%) had them to treat pyothorax. In terms of diagnosing pleurisy, the causative microorganism of origin was identified via thoracoscopy in only three of 12 (25.0%) patients. For diagnosing pyothorax, the causative microorganism was identified in 7 of 18 (38.9%) patients. Methicillin-resistant Staphylococcus aureus was the most common causative microorganism identified. The treatment success rates were very high, ranging between 94.4 and 100%, whereas the identification rate of the causative microorganisms behind infections was low, ranging between 25.0 and 38.9%. The most frequent adverse events included perioperative hypoxaemia and pain. There were two (6.7%) serious adverse events of grade ≥ 3, but none resulted in death.
    CONCLUSIONS: The efficacy of managing intrathoracic infections through thoracoscopy under local anaesthesia is commendable. Nonetheless, the diagnostic accuracy of the procedure, regarding the precise identification of the causative microorganisms responsible for intrathoracic infections, persists at a notably low level, presenting a substantial clinical hurdle.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:本研究调查了胸骨骼肌质量作为肌少症标志物对胸膜脓胸术后死亡率的影响。
    方法:所有在2020年1月至2022年12月期间在一个三级转诊中心接受胸膜脓胸手术的连续患者(n=103)均符合本研究的条件。通过术前计算机断层扫描确定胸部骨骼肌质量指数(TSMI)。回顾性分析TSMI等潜在危险因素对术后院内死亡率的影响。
    结果:本研究共纳入97例患者。住院死亡率为13.4%。在单变量分析中,术前TSMI值低(p=0.020),术前血小板水平(p=0.027)和血清总蛋白水平(p=0.046)较低,术前美国麻醉医师协会(ASA)级别较高(p=0.007)是统计学上显著的死亡危险因素.在多变量分析中,只有TSMI(p=0.038,OR0.933,95%CI:0.875-0.996)和低血小板(p=0.031,OR0.944,95%CI:0.988-0.999)仍然是死亡率的独立预后因素.
    结论:TSMI是胸膜脓胸患者术后死亡的重要预后危险因素。TSMI可能适用于这种具有高发病率和死亡率的疾病的风险分层,这可能对选择最佳治疗策略有进一步的影响。
    BACKGROUND: This study investigated the role of the thoracic skeletal muscle mass as a marker of sarcopenia on postoperative mortality in pleural empyema.
    METHODS: All consecutive patients (n = 103) undergoing surgery for pleural empyema in a single tertiary referral center between January 2020 and December 2022 were eligible for this study. Thoracic skeletal muscle mass index (TSMI) was determined from preoperative computed tomography scans. The impact of TSMI and other potential risk factors on postoperative in-hospital mortality was retrospectively analyzed.
    RESULTS: A total of 97 patients were included in this study. The in-hospital mortality rate was 13.4%. In univariable analysis, low values for preoperative TSMI (p = 0.020), low preoperative levels of thrombocytes (p = 0.027) and total serum protein (p = 0.046) and higher preoperative American Society of Anesthesiologists (ASA) category (p = 0.007) were statistically significant risk factors for mortality. In multivariable analysis, only TSMI (p = 0.038, OR 0.933, 95% CI: 0.875-0.996) and low thrombocytes (p = 0.031, OR 0.944, 95% CI: 0.988-0.999) remained independent prognostic factors for mortality.
    CONCLUSIONS: TSMI was a significant prognostic risk factor for postoperative mortality in patients with pleural empyema. TSMI may be suitable for risk stratification in this disease with high morbidity and mortality, which may have further implications for the selection of the best treatment strategy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Multicenter Study
    背景:电视胸腔镜手术是晚期脓胸的广泛推荐治疗方法。然而,只有少数研究评估了接受电视胸腔镜手术的脓胸患者的预后因素.此外,没有研究评估直接出院回家的预测因素.患者和方法:这项多中心回顾性队列研究包括161例脓胸患者,他们在5家急诊医院接受了电视胸腔镜手术。主要结果是直接出院回家的可能性。次要结果是手术后的住院时间。我们广泛评估了术前因素,并对直接出院回家进行了单变量逻辑回归,对术后住院时间进行了单变量伽马回归。结果:在161名患者中,74.5%直接出院回家。年龄(>70岁;-24.3%);精神状态改变(-33.4%);血尿素氮(>22.4mg/dL;-19.4%);胸膜pH(<7.2;-17.6%)与不直接出院的高概率相关。发热(15.2%)和白蛋白(>2.7g/dL;20.2%)与直接出院的高概率相关。手术后的中位住院时间为19天。年龄(>70岁;6.2天);精神状态改变(5.6天);化脓(2.7天);胸膜厚度(>2cm;5.1天);支气管瘘(14.6天);白蛋白(>2.7g/dL;3.1天);和C反应蛋白(>20mg/dL;3.6天)与术后住院时间延长相关。结论:医师应考虑使用这些预后因素来预测脓胸患者的非直接出院。
    Background: Video-assisted thoracoscopic surgery is a widely recommended treatment for empyema in advanced stages. However, only a few studies have evaluated prognostic factors among patients with empyema who underwent video-assisted thoracoscopic surgery. Furthermore, no studies have evaluated predictors of direct discharge home. Patients and Methods: This multicenter retrospective cohort study included 161 patients with empyema who underwent video-assisted thoracoscopic surgery in five acute-care hospitals. The primary outcome was the probability of direct discharge home. The secondary outcome was the length of hospital stay after surgery. We broadly assessed pre-operative factors and performed univariable logistic regression for the direct discharge home and univariable gamma regression for the length of hospital stay after surgery. Results: Of the 161 included patients, 74.5% were directly discharged home. Age (>70 years; -24.3%); altered mental status (-33.4%); blood urea nitrogen (>22.4 mg/dL; -19.4%); and pleural pH (<7.2; -17.6%) were associated with high probabilities of not being directly discharged home. Fever (15.2%) and albumin (> 2.7 g/dL; 20.2%) were associated with high probabilities of being directly discharged home. The median length of stay after surgery was 19 days. Age (>70 years; 6.2 days); altered mental status (5.6 days); purulence (2.7 days); pleural thickness (>2 cm; 5.1 days); bronchial fistula (14.6 days); albumin (>2.7 g/dL; 3.1 days); and C-reactive protein (>20 mg/dL; 3.6 days) were associated with a longer post-operation hospital stay. Conclusions: Physicians should consider using these prognostic factors to predict non-direct discharge to the home for patients with empyema.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Observational Study
    关于中药治疗哺乳期急性乳腺炎和乳腺脓肿的作用的信息是有限的;因此,本研究采用观察性研究,分析瓜楼消勇汤联合无痛哺乳手法治疗哺乳期急性乳腺炎及乳腺脓肿的临床疗效。本研究纳入了2021年10月至2022年10月期间41例哺乳期急性乳腺炎和乳腺脓肿患者,这些患者均采用瓜楼消勇汤和无痛哺乳手法治疗。年龄,胎儿时间(初产/多胎),分娩方式(剖宫产/阴道分娩),发病时间,乳房肿块直径,皮疹直径,体温,视觉模拟评分,血常规,C反应蛋白,降钙素原,牛奶中的细菌培养,对这些患者的B超等数据进行统计学分析。治疗后,这些患者的乳房肿块直径明显下降,皮疹直径减小或消失,体温下降或恢复到正常范围,视觉模拟评分也有所下降。此外,这些患者的白细胞总数减少,中性粒细胞百分比减少,C反应蛋白,治疗后降钙素原。此外,大多数病人牛奶中的细菌消失了,B超无异常。除2例乳腺脓肿患者分别在患侧停止母乳喂养1天和3天外,所有其他患者继续为婴儿提供母乳,在这些婴儿中没有观察到不良反应。在哺乳期急性乳腺炎及乳腺脓肿的治疗中,采用瓜楼消勇汤联合无痛哺乳手法可取得良好的临床效果。这种综合疗法有很好的疗效,短期治疗,低成本,以及避免疼痛的极大便利,住院治疗,对泌乳的影响,乳房瘢痕和其他不良后果。
    Information on the effects of Chinese medicine in the treatment of lactational acute mastitis and breast abscess is limited; thus, we conducted an observational study to analyze the clinical efficacy of Gualou Xiaoyong Decoction combined with painless lactation manipulation in the treatment of lactational acute mastitis and breast abscess. A total of 41 patients with lactational acute mastitis and breast abscess who were treated with Gualou Xiaoyong Decoction and painless lactation manipulation from October 2021 to October 2022 were included in this study. The age, fetal times(primiparous/multiparous), delivery mode (cesarean section/vaginal delivery), onset time, breast lump diameter, skin rash diameter, body temperature, visual analogue score, blood routine, C-reactive protein, procalcitonin, bacterial culture in milk, B ultrasound and other data of these patients were statistically analyzed. After treatment, the breast lump diameter of these patients decreased significantly, the skin rash diameter was reduced or disappeared, the body temperature decreased or returned to a normal range, and the visual analogue score also decreased. Besides, these patients had a decreased total number of white blood cells and a reduced percentage of neutrophils, C-reactive protein, and procalcitonin after treatment. In addition, bacteria in the milk of most patients disappeared, and there was no abnormality in B ultrasonic imaging. Except for 2 patients with breast abscess who stopped breastfeeding on the affected side for 1 day and 3 days respectively, all other patients continued to provide breast milk for their infants, and no adverse reactions were observed in these infants. The combination of Gualou Xiaoyong Decoction and painless lactation manipulation can achieve favorable clinical effects in the treatment of lactational acute mastitis and breast abscess. This combined therapy has good efficacy, short course of treatment, low costs, and great convenience with the avoidance of pain, hospitalization, influence on lactation, breast scar and other adverse outcomes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Multicenter Study
    背景:由于先前随机对照试验和观察性研究的局限性,即时电视辅助胸腔镜手术(VATS)对现实环境中脓胸患者的有效性尚不清楚.
    目的:本研究旨在评估即时VATS是否能改善脓胸患者的临床预后。
    方法:这项多中心回顾性队列研究包括2006年至2021年间来自6家医院的744例医生诊断为脓胸的患者。暴露是在脓胸诊断后3天内进行的VATS,主要结局是30天死亡率,次要结局是90天死亡率,住院时间,以及从诊断到出院的时间。我们使用倾向得分加权来解释潜在的混杂因素。对于结果分析,我们对死亡率结局采用logistic回归,对天数采用γ回归.
    结果:在744名患者中,53(7.1%)在3天内接受了VATS,691例(92.9%)最初接受保守治疗.在倾向得分加权后,即时VATS和初始保守治疗组的30天和90天死亡率差异为1.18%(95%置信区间[CI],-10.7至13.0%)和-0.08%(95%CI,-10.3至10.2%),分别。住院时间和从诊断到出院的时间差异分别为-3.22(95%CI,-6.19至-0.25天)和-5.04天(95%CI,-8.19至-1.90天),分别。
    结论:我们的现实世界研究表明,立即进行VATS减少了住院时间和从诊断到出院的时间。考虑到样本小和国家之间协议的差异,需要进一步的大规模研究.
    Because of limitations in previous randomised controlled trials and observational studies, the effectiveness of immediate video-assisted thoracoscopic surgery (VATS) for patients with empyema in real-world settings remains unclear.
    This study aimed to evaluate whether immediate VATS improves clinical outcomes in patients with empyema.
    This multicentre retrospective cohort study included 744 patients with physician-diagnosed empyema from six hospitals between 2006 and 2021. The exposure was VATS performed within 3 days of empyema diagnosis, the primary outcome was 30-day mortality, and secondary outcomes were 90-day mortality, length of hospital stay, and time from diagnosis to discharge. We used propensity score weighting to account for potential confounders. For outcome analyses, we used logistic regression for mortality outcomes and gamma regression for the number of days.
    Among the 744 patients, 53 (7.1%) underwent VATS within 3 days, and 691 (92.9%) initially received conservative treatment. After propensity score weighting, the differences in 30- and 90-day mortalities between the immediate VATS and initial conservative treatment groups were 1.18% (95% confidence interval [CI], -10.7 to 13.0%) and -0.08% (95% CI, -10.3 to 10.2%), respectively. The differences in length of hospital stay and time from diagnosis to discharge were -3.22 (95% CI, -6.19 to -0.25 days) and -5.04 days (95% CI, -8.19 to -1.90 days), respectively.
    Our real-world study showed that immediate VATS reduced the length of hospital stay and the time from diagnosis to discharge. Considering the small sample and differences in protocols between countries, further large-scale studies are warranted.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:尽管普雷沃氏菌属是一般人类菌群的一部分,这种厌氧革兰氏阴性细菌的种类已被描述为持续非产褥期乳房脓肿的原因。收集点状样本并测试这些样本中的厌氧细菌,不属于非典型乳腺脓肿的常见诊断工作流程。致病厌氧微生物可能仍不清楚,患者可以用多种抗生素不足和/或广泛的外科手术治疗。这项关于普雷沃氏菌诱导的乳腺脓肿的队列研究的目的是获得对诊断程序和治疗的更多见解。
    方法:对2015年至2021年间普雷沃氏菌诱发的乳腺脓肿患者的病历进行回顾性分析,诊断程序,治疗和结果。
    结果:纳入21例患者。通过培养确定了Prevotella的6个亚种。对阿莫西林/克拉维酸的敏感性较高(100%,n=12)。9名患者(43%)接受了抗生素治疗,8例患者(38%)使用抗生素和切开引流,和4例患者(19%),只有切口和引流。9例患者(43%)出现复发,其中五名患者接受了抗生素治疗,三名患者接受了手术治疗。与未复发的患者相比,复发患者的平均抗生素给药时间明显缩短(5.6天vs.19.5天,p=0.039)。
    结论:在非典型乳腺脓肿中,特异性厌氧培养应该是常见的做法,以确认Prevotella的种类。高复发率强调需要进一步研究最佳治疗方法。可以考虑延长抗生素的持续时间,阿莫西林/克拉维酸似乎是首选。
    OBJECTIVE: Although the genus Prevotella is part of the general human microbiota, species of this anaerobic gram-negative bacterium have been described as causes of persisting nonpuerperal breast abscesses. Collecting punctate samples and testing these samples for anaerobic bacteria is not part of the common diagnostic workflow in atypical breast abscesses. The causative anaerobic micro-organism can remain unclear and patients can be treated with multiple inadequate antibiotics and/or extensive surgical procedures. The aim of this cohort study of Prevotella induced breast abscesses is to gain more insights into the diagnostic procedures and treatment.
    METHODS: Medical charts of patients with a Prevotella induced breast abscess between 2015 and 2021, were retrospectively reviewed on patient characteristics, diagnostic procedures, treatment and outcome.
    RESULTS: Twenty-one patients were included. Six subspecies of Prevotella were determined by culturing. High susceptibility was observed for amoxicillin/clavulanic acid (100%, n = 12). Nine patients (43%) were treated with antibiotics, eight patients (38%) with antibiotics and incision and drainage, and four patients (19%) with only incision and drainage. Recurrence was observed in nine patients (43%), of whom five patients were treated with antibiotics and three patients had surgery. The mean duration of antibiotic administration in patients with recurrence was significantly shorter compared to those without recurrence (5.6 days vs. 19.5 days, p = 0.039).
    CONCLUSIONS: Specific anaerobic culturing should be common practice in atypical breast abscesses to confirm Prevotella species. The high recurrence rate emphasizes the need of further research for optimal treatment. Prolonged duration of antibiotics could be considered and amoxicillin/clavulanic acid seems to be the first choice.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Observational Study
    背景:胸膜感染,胸膜腔感染,经常用抗生素和胸腔引流。如果排水不足,在手术干预前考虑胸膜内纤维蛋白溶解剂。然而,纤溶单药治疗的有效性仍存在争议.因此,我们旨在研究胸膜感染患者尿激酶单药治疗与治疗失败之间的关系.
    方法:在这项回顾性观察研究中,胸膜感染患者接受胸管插入术分为两组,包括接受或不接受胸膜腔内注射尿激酶的患者。倾向评分重叠加权用于平衡组间的基线特征。治疗失败的定义为院内死亡和手术转诊的复合主要结局。
    结果:在94例患者中,尿激酶和非尿激酶组分别为67和27例,分别。尿激酶单药治疗改善了组间的复合结局(19.4%vs.48.1%,p=0.01)。在使用倾向得分重叠加权进行调整后,与非尿激酶组相比,尿激酶单药治疗改善了复合结局(19.0%vs.59.5%,p=0.003)。
    结论:尿激酶单药治疗可能是胸膜感染患者的重要非手术治疗选择。
    背景:参与者进行回顾性登记。
    BACKGROUND: Pleural infection, an infection of the pleural space, is frequently treated with antibiotics and thoracic tube drainage. In case of insufficient drainage, an intrapleural fibrinolytic agent is considered before surgical intervention. However, the effectiveness of fibrinolytic monotherapy is still controversial. Therefore, we aimed to examine the association between urokinase monotherapy and treatment failure in patients with pleural infection.
    METHODS: In this retrospective observational study, patients with pleural infection underwent chest tube insertion were divided into two groups including patients treated with or without intrapleural instillation of urokinase. The propensity score overlap weighting was used to balance the baseline characteristics between the groups. Treatment failure was defined by the composite primary outcome of in-hospital death and referral for surgery.
    RESULTS: Among the 94 patients, 67 and 27 patients were in the urokinase and non-urokinase groups, respectively. Urokinase monotherapy improved the composite outcome between the groups (19.4% vs. 48.1%, p = 0.01). After adjusting using propensity score overlap weighting, urokinase monotherapy improved the composite outcome compared to the non-urokinase group (19.0% vs. 59.5%, p = 0.003).
    CONCLUSIONS: Urokinase monotherapy can be an important nonsurgical treatment option for patients with pleural infection.
    BACKGROUND: The participants were retrospectively registered.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Multicenter Study
    背景:由于各种原因对脓胸患者进行胸部计算机断层扫描。然而,其对脓胸患者预后的预测能力尚未评估.
    目的:评估计算机断层扫描结果的预测能力(胸膜厚度,定位,叶间胸腔积液,肺脓肿,和支气管胸膜瘘)用于脓胸的90天死亡率。
    方法:这项多中心回顾性队列研究是在日本六家急性护理医院进行的。我们纳入了确诊脓胸的患者,这些患者在诊断后7天内接受了胸部计算机断层扫描。影像学检查结果定义为胸膜厚度,定位,叶间胸腔积液,肺脓肿,或者支气管胸膜瘘.一位放射科医师在没有患者信息的情况下解释了计算机断层扫描。主要结果是90天死亡率。我们使用逻辑回归进行了或不进行早期胸外科手术的调整,计算了每个计算机断层扫描发现的存在和不存在之间的90天死亡率差异。
    结果:本研究共纳入711例患者。27%的患者进行了胸外科手术,90天死亡率为10%。不进行或控制早期胸外科手术的90天死亡率差异如下:胸膜厚度,3.09%(95%置信区间:-1.35-7.54%),2.70%(-1.80%至7.20%);定位,-4.01%(-8.61%至0.60%),-3.80%(-8.41-0.81%);叶间胸腔积液,-9.15%(-14.58%至-3.72%),-8.96%(-14.39%至-3.53%);肺脓肿,7.04%(-1.16-15.2%),6.86%(-1.34-15.05%);支气管胸膜瘘,13.80%(7.66-19.94%),13.63%(7.50-19.77%),分别。
    结论:虽然叶间胸腔积液可预测90天死亡率较低,而与早期胸外科手术无关,支气管胸膜瘘的存在预示脓胸患者90天死亡率较高.我们的结果值得进一步验证。
    Rationale: Chest computed tomography is performed in patients with empyema for various reasons. However, its predictive ability for patient outcomes in empyema has not been evaluated. Objectives: To evaluate the predictive ability of computed tomography findings (pleural thickness, loculation, interlobar pleural effusion, lung abscess, and bronchopleural fistula) for 90-day mortality in empyema. Methods: This multicenter retrospective cohort study was conducted across six acute care hospitals in Japan. We included patients with confirmed empyema diagnoses who underwent chest computed tomography within 7 days of diagnosis. Imaging findings were defined as pleural thickness, loculation, interlobar pleural effusion, lung abscess, or bronchopleural fistula. One radiologist interpreted the computed tomography scans without patient information. The primary outcome was 90-day mortality. We calculated the differences in 90-day mortality between the presence and absence of each computed tomography finding using logistic regression with or without adjustment for early thoracic surgery. Results: A total of 711 patients were included in our study. Thoracic surgery was performed in 27% of patients, and the 90-day mortality rate was 10%. The differences (95% confidence intervals) in 90-day mortality without and with adjustment for early thoracic surgery were as follows: pleural thickness, 3.09% (-1.35% to 7.54%) and 2.70% (-1.80% to 7.20%); loculation, -4.01% (-8.61% to 0.60%) and -3.80% (-8.41% to 0.81%); interlobar pleural effusion, -9.15% (-14.58% to -3.72%) and -8.96% (-14.39% to -3.53%); lung abscess, 7.04% (-1.16% to 15.2%) and 6.86% (-1.34% to 15.05%); and bronchopleural fistula, 13.80% (7.66% to 19.94%) and 13.63% (7.50% to 19.77%), respectively. Conclusions: Although interlobar pleural effusion predicted lower 90-day mortality regardless of early thoracic surgery, the presence of bronchopleural fistula predicted higher 90-day mortality with empyema. Our results warrant further validation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号